PP01.84 Tepotinib + Osimertinib in EGFR-mutant NSCLC with METAmplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis

Autor: Kim, Tae Min, Guarneri, Valentina, Voon, Pei Jye, Lim, Boon Khaw, Yang, Jin-ji, Wislez, Marie, Huang, Cheng, Liam, Chong Kin, Mazieres, Julien, Tho, ye Mun, Hayashi, Hidetoshi, Nguyen, Nhung, Chia, Puey Ling, de Marinis, Filippo, Raskin, Jo, Zhou, Qinghua, Finocchiaro, Giovanna, Le, Xiuning, Tan, Daniel, O’Hara, Richard M., Brutlach, Sabine, O’Brate, Aurora, Adrian, Svenja, Berghoff, Karin, Ellers-Lenz, Barbara, Karachaliou, Niki, Wu, Yi-Long
Zdroj: Journal of Thoracic Oncology; July 2024, Vol. 19 Issue: 7, Number 7 Supplement 1 pe38-e38, 1p
Databáze: Supplemental Index